InvestorsHub Logo
Followers 138
Posts 23166
Boards Moderated 0
Alias Born 04/08/2004

Re: BAR123 post# 452623

Saturday, 02/24/2024 11:49:23 AM

Saturday, February 24, 2024 11:49:23 AM

Post# of 462570
Summary
Anavex's full Alzheimer's 2b/3 data is set to be published in a peer-reviewed journal soon.

The company is likely positioned for Alzheimer's approval in Europe.

We expect benefit of Blarcamesine over mAbs in cost, safety, administration, and efficacy will allow it to explosively supersede the antibodies in market penetration.

A phase 2 Schizophrenia trial testing Anavex 3-71 is imminent.

Further Rett Syndrome guidance is expected in 2024 which may result in approval.

Further, more in-depth analysis can be found in the 2022 and 2023 archive folders.

https://www.sotcanalytics.com/home

Good luck and GOD bless,
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News